4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0000950170-25-113130
Chief R&D Officer sold 485 shares at $30.10 ($14,599)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-09-02 | Sale : show line 1 in the form 10b5-1 | −485 | $30.10 | $14,599 | 19,183 | D |
| Open-market sales · 485 sh · avg $30.10 · $14,599 | ||||||
Loading xslF345X05/ownership.xml…